HER2-Positive Breast Cancer | Clinical

December 09, 2020

Despite having similar disease characteristics and treatment patterns, elderly patients with HER2-positive advanced breast cancer aged ≥ 70 years experienced shorter chemotherapy durations than patients under the age of 70, as well as, poorer overall survival, and increased rates of adverse events in a real-world study.

November 30, 2020

The most interesting developments and approvals in breast cancer treatment in the last year and expectations regarding data that will be presented on at the upcoming 2020 San Antonio Breast Cancer Symposium.

November 17, 2020

Hope Rugo, MD, discusses her key takeaways in the field of HER2-positive breast cancer.

November 14, 2020

Although the dual HER2 blockade combination is now considered a standard regimen for the treatment of patients with HER2-positive early-stage breast cancer, there are limited efficacy data regarding the use of the regimen in Asian populations.

November 10, 2020

A phase 3 study was initiated for a head-to-head comparison of trastuzumab deruxtecan versus T-DM1 as adjuvant treatment of a subset of patients with HER2-positive early breast cancer.

November 02, 2020

In an interview with Targeted Oncology, William J. Gradishar, MD, discussed the current treatment options for patients with HER2-positive breast cancer, including the recently approved therapies from the FDA. He also shared his insights on treating patients with brain metastases, in particular.

October 28, 2020

During a recent tweet chat, Sara M. Tolaney, MD, MPH, joined Targeted Oncology for the discussion of a 39-year-old woman with relapsed/refractory HR-negative/HER2-positive metastatic breast cancer.

October 20, 2020

Until recently, few options existed for patients with HER2-positive breast cancer who progressed on earlier lines of therapy. Recent approvals of 3 drug combinations offer new tools that may prolong life and control brain metastases across lines of therapy.

October 13, 2020

A number of targeted agents have been approved in the setting of metastatic breast cancer, which has allowed for more personalized treatment approaches and underscores the importance of genomic testing.

October 03, 2020

Although HER2 positivity has been identified as a predictive factor of response to chemotherapy, it remains controversial considering that responses to chemotherapy can vary in patients with certain disease characteristics.